0 Valutazioni
ID

34016

Descrizione

Study ID: 103974 (primary study) Clinical Study ID: 103974 Study Title: Demonstrate non-inferiority of Men-C immune response of Hib-MenC with Infanrix™-IPV versus a licensed Men-C vaccine with Pediacel™ when given at 2, 3, 4 months and the immunogenicity of Hib-MenC when given as a booster dose at 12-15 months Patient Level Data: Study Listed on ClinicalStudyDataRequest.com Clinicaltrials.gov Identifier: NCT00258700 Sponsor: GlaxoSmithKline Collaborators: N/A Phase: Phase 3 Study Recruitment Status: Completed Generic Name: Haemophilus influenzae Type b, Meningococcal C-Tetanus Toxoid Conjugate Vaccine Trade Name: BIO HIB-MENC-TT; Menitorix Study Indication: Haemophilus influenzae type b; Neisseria Meningitidis

Keywords

versioni (1)
  1. 11/01/19 11/01/19 -
Titolare del copyright

GSK group of companies

Caricato su

11 gennaio 2019

DOI

Per favore, per richiedere un accesso.

Licenza

Creative Commons BY-NC 3.0
Commenti del modello :

Puoi commentare il modello dati qui. Tramite i fumetti nei gruppi di articoli e articoli è possibile aggiungere commenti a quelli in modo specifico.

Torna ai commenti del modello
Commenti del gruppo di articoli per :

Commenti dell'articolo per :

  • i più nuovi
  • i più vecchi
  • Popolare
  • i più nuovi
    • i più nuovi
    • i più vecchi
    • Popolare

    Non ci sono commenti

    Per scaricare i modelli di dati devi essere registrato. Per favore accesso o registrati GRATIS.

    Primary & Booster Immunogenicity of Hib-MenC vs a Licensed Men-C Vaccine - 103974

    Inglese

    Visit 6: Eligibility Check, Laboratory Test

    1 moduli  
    Administrative data
    Descrizione

    Administrative data

    Visit Number
    Descrizione

    Visit Number

    Tipo di dati

    integer

    Day
    Descrizione

    Day

    Tipo di dati

    text

    Subject Number
    Descrizione

    Subject Number

    Tipo di dati

    integer

    Date of Visit
    Descrizione

    Date of Visit

    Tipo di dati

    date

    Check for Study Continuation
    Descrizione

    Check for Study Continuation

    Did the subject return for Visit 6?
    Descrizione

    Did the subject return for Visit 6?

    Tipo di dati

    boolean

    If No, please tick ONE most appropriate reason
    Descrizione

    If No, please tick ONE most appropriate reason

    Tipo di dati

    text

    If Other, please specify
    Descrizione

    If Other, please specify

    Tipo di dati

    text

    If SAE, record the SAE number
    Descrizione

    If SAE, record the SAE number

    Tipo di dati

    integer

    If non-SAE, please record the AE number
    Descrizione

    If non-SAE, please record the AE number

    Tipo di dati

    integer

    Please tick who took the decision
    Descrizione

    Please tick who took the decision

    Tipo di dati

    text

    Elimination Criteria During The Study
    Descrizione

    Elimination Criteria During The Study

    The following criteria should be checked at each visit subsequent to the first visit.
    Descrizione

    If any of the criteria become applicable during the study, it will not require withdrawal of the subject from the study but may determine a subject's evaluability in the according-to-protocol (ATP) analysis.

    Tipo di dati

    text

    1. Use of any investigational or non-registered product (drug or vaccine) other than the study vaccine(s) during the study period
    Descrizione

    1. Use of any investigational or non-registered product (drug or vaccine) other than the study vaccine(s) during the study period

    Tipo di dati

    text

    2. Chronic administration (defined as more than 14 days) or immunodepressants or other imminodefying drugs during the study period.
    Descrizione

    2. Chronic administration (defined as more than 14 days) or immunodepressants or other imminodefying drugs during the study period.

    Tipo di dati

    text

    3. Administration of a vaccine not foreseen by the study protocol during the period starting from 30 days before each dose of vaccine(s) and ending 30 days after
    Descrizione

    3. Administration of a vaccine not foreseen by the study protocol during the period starting from 30 days before each dose of vaccine(s) and ending 30 days after

    Tipo di dati

    text

    4. Administration of immunoglobulins and/or any blood products during the study period
    Descrizione

    4. Administration of immunoglobulins and/or any blood products during the study period

    Tipo di dati

    text

    Laboratory Tests - Blood
    Descrizione

    Laboratory Tests - Blood

    Has a blood sample been taken?
    Descrizione

    Has a blood sample been taken?

    Tipo di dati

    boolean

    Date blood sample taken
    Descrizione

    please fill in only if different from visit date

    Tipo di dati

    date

    Ritorna all'inizio della pagina

    Similar models

    Visit 6: Eligibility Check, Laboratory Test

    1 moduli
    Name
    genere
    Description | Question | Decode (Coded Value)
    Tipo di dati
    Alias
    Item Group
    Administrative data
    Item
    Visit Number
    integer
    Visit Number
    Code List
    Visit Number
    CL Item
    Visit 6 (1)
    Item
    Day
    text
    Day
    Code List
    Day
    CL Item
    42-56 days after Visit 5 (1)
    Subject Number
    Item
    Subject Number
    integer
    Date of Visit
    Item
    Date of Visit
    date
    Item Group
    Check for Study Continuation
    Did the subject return for Visit 6?
    Item
    Did the subject return for Visit 6?
    boolean
    Item
    If No, please tick ONE most appropriate reason
    text
    If No, please tick ONE most appropriate reason
    Code List
    If No, please tick ONE most appropriate reason
    CL Item
    Serious Adverse Event (SAE) (1)
    CL Item
    Non-Serious Adverse Event (Non-SAE) (2)
    CL Item
    Other (e.g.withdrawal,protocol violation) (3)
    If Other, please specify
    Item
    If Other, please specify
    text
    If SAE, record the SAE number
    Item
    If SAE, record the SAE number
    integer
    If non-SAE, please record the AE number
    Item
    If non-SAE, please record the AE number
    integer
    Item
    Please tick who took the decision
    text
    Please tick who took the decision
    Code List
    Please tick who took the decision
    CL Item
    Investigator (1)
    CL Item
    Parents / Guardians (2)
    Item Group
    Elimination Criteria During The Study
    Item
    The following criteria should be checked at each visit subsequent to the first visit.
    text
    The following criteria should be checked at each visit subsequent to the first visit.
    Code List
    The following criteria should be checked at each visit subsequent to the first visit.
    CL Item
    Use of any investigational or non-registered product (drug or vaccine) other than the study vaccine(s) during the study period (1)
    CL Item
    Chronic administration (defined as more than 14 days) or immunodepressants or other imminodefying drugs during the study period. (For corticosteroids, this will mean prednisone, or equivalent, ≥0.5 mg/kg/day. Inhaled and topical steroids are allowed.) (2)
    Item
    1. Use of any investigational or non-registered product (drug or vaccine) other than the study vaccine(s) during the study period
    text
    1. Use of any investigational or non-registered product (drug or vaccine) other than the study vaccine(s) during the study period
    Code List
    1. Use of any investigational or non-registered product (drug or vaccine) other than the study vaccine(s) during the study period
    CL Item
    Applicable (1)
    CL Item
    Not applicable (2)
    Item
    2. Chronic administration (defined as more than 14 days) or immunodepressants or other imminodefying drugs during the study period.
    text
    2. Chronic administration (defined as more than 14 days) or immunodepressants or other imminodefying drugs during the study period.
    Code List
    2. Chronic administration (defined as more than 14 days) or immunodepressants or other imminodefying drugs during the study period.
    CL Item
    Applicable (1)
    CL Item
    Not applicable (2)
    Item
    3. Administration of a vaccine not foreseen by the study protocol during the period starting from 30 days before each dose of vaccine(s) and ending 30 days after
    text
    3. Administration of a vaccine not foreseen by the study protocol during the period starting from 30 days before each dose of vaccine(s) and ending 30 days after
    Code List
    3. Administration of a vaccine not foreseen by the study protocol during the period starting from 30 days before each dose of vaccine(s) and ending 30 days after
    CL Item
    Applicable (1)
    CL Item
    Not applicable (2)
    Item
    4. Administration of immunoglobulins and/or any blood products during the study period
    text
    4. Administration of immunoglobulins and/or any blood products during the study period
    Code List
    4. Administration of immunoglobulins and/or any blood products during the study period
    CL Item
    Applicable (1)
    CL Item
    Not applicable (2)
    Item Group
    Laboratory Tests - Blood
    Has a blood sample been taken?
    Item
    Has a blood sample been taken?
    boolean
    Date blood sample taken
    Item
    Date blood sample taken
    date
    Ritorna all'inizio della pagina 

    Aiuto

    Do you need help on how to use the search function? Please watch the corresponding tutorial video for more details and learn how to use the search function most efficiently.

    Watch Tutorial